The St. Helier, Jersey-based company said that the newly launched grants include the AACR-Novocure Tumor Treating Fields Research Grant, the AACR-Novocure Career Development Award for Tumor Treating Fields Research, the AACR-Novocure Tumor Treating Fields Research Fellowship and the AACR-Novocure Discovery Grant.
The deadline for the grants closes on January 23, and will support research focused on preclinical applications of tumor treating fields in cancer that are either basic or translational in nature.
“At Novocure, we are striving to extend survival in some of the most aggressive forms of cancer through the development of Tumor Treating Fields. This inaugural grant program with AACR allows us to support independent researchers as they advance basic and translational research on Tumor Treating Fields. The program is intended to provide a deeper understanding of the mechanism of action of Tumor Treating Fields and to accelerate the development of new treatment strategies to advance therapeutic options for cancer. I look forward to announcing the grant recipients at the AACR Annual Meeting 2019,” Novocure chief science officer Dr. Eilon Kirson said in a press release.
In October, Novocure released results from a post-hoc analysis of its EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma, touting an association between higher doses of Tumor Treating Fields and improved overall survival.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.